Argos Therapeutics, Inc. Share Price

ARGSQ

US0402212023

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-6.22%	+78.50%

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI

Valuation: Argos Therapeutics, Inc.

Market Cap	318K 279K 262K 240K 448K 30.42M 451K 3.15M 1.22M 15.51M 1.19M 1.17M 50.29M	P/E 2016	-2.96x	P/E 2017	-0.22x
Enterprise Value	4.58M 4.02M 3.78M 3.46M 6.46M 439M 6.51M 45.44M 17.61M 224M 17.22M 16.84M 726M	EV / Sales 2016	200x	EV / Sales 2017	9.19x
Free-Float	88.73%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news: Argos Therapeutics, Inc.

24/09/19	Argos Therapeutics, Inc. Went Out of Business	CI
24/09/19	First Amended Liquidation Plan Approved for Argos Therapeutics, Inc.	CI
30/08/19	First Amended Liquidation Plan Filed by Argos Therapeutics, Inc.	CI
21/03/19	Revised Disclosure Statement Approved on Interim Basis for Argos Therapeutics, Inc.	CI
15/03/19	Liquidation Plan and Disclosure Statement Filed by Argos Therapeutics, Inc.	CI
12/02/19	Genexine Inc. and SCM Lifescience Co. completed the acquisition of substantially all of the assets of Argos Therapeutics Inc.	CI
23/01/19	Motion for Asset Sale Approved for Argos Therapeutics, Inc.	CI
22/01/19	Notice of Successful Bidder Filed by Argos Therapeutics, Inc.	CI
21/01/19	Genexine Inc. and SCM Lifescience Co. entered into an asset purchase agreement to acquire substantially all of the assets of Argos Therapeutics Inc. for $11.3 million.	CI
21/01/19	CELLSCRIPT, LLC and Immune and Cell Therapies, LLC cancelled the acquisition of substantially all of the non-cash assets of Argos Therapeutics, Inc..	CI
20/12/18	Bidding Procedure Approved for Argos Therapeutics, Inc.	CI
06/12/18	Argos Therapeutics, Inc. will Change its Ticker to ARGSQ from ARGS	CI
03/12/18	Argos Therapeutics, Inc. Announces Management Changes	CI

More news

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
ARGSQ Stock

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGOS THERAPEUTICS, INC.	-.--%	-6.22%	-	-	567K
REGENERON PHARMACEUTICALS, INC.	-0.26%	+3.51%	+41.19%	-2.79%	80.07B
MODERNA, INC.	-0.25%	+25.06%	+606.13%	+82.13%	72.7B
CSL LIMITED	-0.07%	+0.88%	-9.23%	-29.20%	60.45B
SAMSUNG BIOLOGICS CO.,LTD.	-1.80%	-3.05%	-14.24%	+26.38%	46.24B
UCB	-0.52%	+0.96%	+2.98%	+164.24%	45.97B
BIOGEN INC.	+0.96%	+5.33%	+63.33%	-11.70%	33.62B
INCYTE CORPORATION	-1.80%	-0.09%	+47.43%	+114.53%	25.26B
INNOVENT BIOLOGICS, INC.	-3.48%	+3.80%	+5.00%	+155.90%	22.95B
SWEDISH ORPHAN BIOVITRUM AB	-1.18%	-2.74%	+56.53%	+96.20%	15.44B
Average	-0.98%	+4.08%	+88.79%	+66.19%	40.27B
Weighted average by Cap.	-0.90%	+6.70%	+125.65%	+50.45%

	2016	2017
Net sales	945K 830K 780K 713K 1.33M 90.57M 1.34M 9.37M 3.63M 46.17M 3.55M 3.47M 150M	1.9M 1.67M 1.57M 1.43M 2.68M 182M 2.7M 18.82M 7.3M 92.76M 7.13M 6.98M 301M
Net income	-53.03M -46.54M -43.75M -40M -74.75M -5.08B -75.3M -526M -204M -2.59B -199M -195M -8.4B	-40.58M -35.61M -33.48M -30.61M -57.2M -3.89B -57.62M -402M -156M -1.98B -152M -149M -6.43B
Net Debt	-13.11M -11.51M -10.82M -9.89M -18.48M -1.26B -18.61M -130M -50.36M -640M -49.23M -48.15M -2.08B	4.27M 3.75M 3.52M 3.22M 6.02M 409M 6.06M 42.29M 16.39M 208M 16.03M 15.67M 676M

Argos Therapeutics, Inc. Share Price

Stocks

ARGSQ

US0402212023

Pharmaceuticals

Valuation: Argos Therapeutics, Inc.

Latest news: Argos Therapeutics, Inc.

Biopharmaceuticals

Financials

Company Profile